StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research report sent to investors on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright cut their price objective on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th.
View Our Latest Analysis on Minerva Neurosciences
Minerva Neurosciences Stock Down 0.8 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, analysts anticipate that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
See Also
- Five stocks we like better than Minerva Neurosciences
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the FTSE 100 index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Are the U.K. Market Holidays? How to Invest and Trade
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.